Currently, there are therapies targeted toward CGRP and its receptor in the prevention of migraine—Erenumab—and considering the association between CGRP and colorectal cancer, they may represent an effective treatment in this type of cancer, but numerous studies and trials with large, heterogeneous patients’ groups must be performed [47,48]. This evidence concerns the gene CALCA and migraine disorder.